Vr Adviser, LLC Tricida, Inc. Transaction History

Vr Adviser, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 15, 2023	BUY	$8.51 - $13.6 $16.3 Million - $26.1 Million	1,917,985 Added 26.89%	9,050,064 $94.8 Million
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $16.3 Million - $26.1 Million	1,917,985 Added 26.89%	9,050,064 $94.8 Million
Q2 2022 May 15, 2023	BUY	$7.31 - $11.85 $52.1 Million - $84.5 Million	7,132,079 New	7,132,079 $69 Million
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $19.3 Million - $31.3 Million	2,637,228 Added 58.67%	7,132,079 $69 Million
Q1 2022 May 16, 2022	BUY	$7.35 - $10.63 $7.35 Million - $10.6 Million	1,000,000 Added 28.61%	4,494,851 $36.9 Million
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $13 Million - $29.7 Million	3,104,144 Added 794.49%	3,494,851 $33.4 Million
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $1.39 Million - $1.81 Million	390,707 New	390,707 $1.81 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.